Stabilized coronavirus spike (S) protein immunogens and related vaccines
AssigneeThe Scripps Research Institute
InventorsLinling He, Jiang Zhu, Ian A. Wilson
Life of this patent
Estimating the term…
Abstract
The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
Claims6
An engineered immunogen polypeptide derived from the spike (S) protein of SARS-CoV-2, comprising a sequence having at least 99% identity to the sequence shown in SEQ ID NO:33;
- wherein the polypeptide does not comprise a SARS-CoV-2 S protein HR2 region corresponding to amino acids 1150-1208 of SEQ ID NO:3;
- wherein the S1/S2 cleavage site sequence corresponding to amino acids 682-687 (RRARSV) of SEQ ID NO:3 is replaced with SEQ ID NO:
- 18 (GSAGSV);
- and wherein the HR1 region comprises a double glycine mutation at positions corresponding to K986G and V987G of SEQ ID NO:
- 3.
A SARS-CoV 2 immunogenic composition, comprising a polypeptide sequence containing from N terminus to C terminus an engineered SARS-CoV-2 spike polypeptide comprising a sequence having at least 99% identity to the sequence shown in SEQ ID NO:33, linker sequence (G4S)2 (SEQ ID NO:22), nanoparticle sequence shown in SEQ ID NO:23, locking domain shown in SEQ ID NO:29, and T cell epitope shown in SEQ ID NO:30;
- wherein the engineered SARS-CoV-2 spike polypeptide does not comprise a SARS-CoV-2 S protein HR2 region corresponding to amino acids 1150-1208 of SEQ ID NO:3;
- wherein the S1/S2 cleavage site sequence corresponding to amino acids 682-687 (RRARSV) of SEQ ID NO:3 is replaced with SEQ ID NO:
- 18 (GSAGSV);
- and wherein the HR1 region comprises a double glycine mutation at positions corresponding to K986G and V987G of SEQ ID NO:
- 3.
A SARS-CoV 2 immunogenic composition, comprising a polypeptide sequence containing from N terminus to C terminus the engineered SARS-CoV-2 spike polypeptide comprising a sequence having at least 99% identity to the sequence shown in SEQ ID NO:33, linker sequence G4S (SEQ ID NO:21), nanoparticle subunit sequence shown in SEQ ID NO:24, locking domain shown in SEQ ID NO:28, and T cell epitope shown in SEQ ID NO:30;
- wherein the engineered SARS-CoV-2 spike polypeptide does not comprise a SARS-CoV-2 S protein HR2 region corresponding to amino acids 1150-1208 of SEQ ID NO:3;
- wherein the S1/S2 cleavage site sequence corresponding to amino acids 682-687 (RRARSV) of SEQ ID NO:3 is replaced with SEQ ID NO:
- 18 (GSAGSV);
- and wherein the HR1 region comprises a double glycine mutation at positions corresponding to K986G and V987G of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.